All Comments by Edward Koo

  1. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies.
  2. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations.
  3. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts.
  4. Trials and Tribulations: Does ADAPT Have to Adapt?
  5. Caspase inhibition protects nerve terminals from in vitro degradation.
  6. PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin.
  7. Abnormal cerebellar signaling induces dystonia in mice.
  8. Antibodies to beta-amyloid decrease the blood-to-brain transfer of beta-amyloid peptide.
  9. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration.
  10. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
  11. Analysis of tau haplotypes in Pick's disease.
  12. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.
  13. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease.
  14. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP).
  15. Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice.